Company news

Tigermed-Jyton Supports China NMPA Approval of Meiyan MED’s Cross-linked Sodium Hyaluronate Gel for Injection

Recently, the Cross-linked Sodium Hyaluronate Gel for Injection developed by Xi'an Meiyan Angel Biotechnology Co., Ltd. (hereinafter referred to as "Meiyan MED") has officially received medical device registration approval from the National Medical Products Administration (NMPA). This product is intended for intradermal injection into the dermis layer of the neck to correct moderate-to-severe transverse neck lines. Tigermed-Jyton provided clinical trial management services, playing a key role in the successful approval of this product.

The newly approved Cross-linked Sodium Hyaluronate Gel for Injection is designed for intradermal dermis layer filling in the neck to address moderate-to-severe transverse neck lines. This approval marks a significant milestone for MEIYAN MED in the dermal filler business segment, representing a substantive step forward in its strategic expansion from existing operations into the dermal filler arena. This product is expected to create synergies with the company's existing maxillofacial repair portfolio, thereby further enriching its product range and optimizing its business layout.

The study team faced 2 major challenges in this clinical trial: patient recruitment and operational standardization. During the recruitment phase, the unique nature of the neck indication often imposed a psychological burden on potential participants. Coupled with stringent inclusion criteria, this placed high demands on the team. To address this, Tigermed-Jyton adopted a holistic approach, devising a systematic recruitment strategy encompassing early-stage communication, trust-building, and screening confirmation. Through transparent interaction and leveraging referrals from participants, we effectively alleviated participants' concerns. A scientific screening process ensured enrollment quality fully complied with the study protocol, while rigorously safeguarding participants' rights and safety.

To overcome the technical difficulties associated with high variability in neck injection procedures, our team developed a standardized operational framework covering the entire clinical workflow. This was based on a deep understanding of the product's characteristics and clinical pain points. Unified specifications were established for all critical dimensions involved in the trial, minimizing operational deviations and effectively enhancing the consistency and traceability of trial data. Leveraging over a decade of industry experience in the medical aesthetics field, a resource network covering more than 60 research sites and over 100 investigators nationwide, and extensive execution experience from over 140 medical aesthetics projects, Tigermed-Jyton implemented rigorous quality control throughout the entire process. This ultimately provided robust support for the product to successfully pass the NMPA registration and approval.

The successful approval of Meiyan MED's Cross-linked Sodium Hyaluronate Gel for Injection is not only a pivotal step for the company in the neck rejuvenation segment but also another classic case for Tigermed-Jyton in the field of medical aesthetics clinical research. Looking ahead, Tigermed-Jyton will continue to uphold our service philosophy of "Service Creates Value," providing professional, rigorous, and efficient full-process clinical services. We are committed to accelerating the market launch of more innovative medical devices and contributing our professional expertise to the world healthcare.

About Meiyan MED

Meiyan MED is a wholly-owned subsidiary of Kontour(Xi'an) Medical Technology Co., Ltd. (Stock Code: 688314), established in 2021 as a flagship entity in medical aesthetics technology. The company has consistently focused on the innovative R&D, lean manufacturing, and commercial operations of Class II and III implantable medical aesthetic devices, empowering the new ecosystem of premium medical aesthetics with cutting-edge bioscience. Positioned in the advanced biomedical materials sector, Meiyan MED is dedicated to fundamental research and technological innovation in biodegradable materials. With a strategic focus on refined facial and neck aesthetics, the company develops comprehensive, safe, and efficient injectable filler solutions. These solutions precisely cater to the diverse aesthetic needs of contemporary consumers—including rejuvenation, firming, contouring, and texture restoration—using the power of science to define natural, youthful tissue texture and reshape the medical aesthetics experience.

References:

China Securities Journal Online, Bulletin No. 2026-037, Kontour(Xi'an) Medical Technology Co., Ltd. Announcement on Voluntary Disclosure of Holding Subsidiary Obtaining Medical Device Registration Certificate.

https://app.cnstock.com/zzb/zgzqb/html/2026-08/26/nw.D110000zgzqb_20260826_4-A14.htm